CSTL icon

Castle Biosciences

20.10 USD
+0.02
0.10%
At close Mar 27, 4:00 PM EDT
After hours
20.10
+0.00
0.00%
1 day
0.10%
5 days
1.21%
1 month
-20.49%
3 months
-25.08%
6 months
-27.85%
Year to date
-28.32%
1 year
-5.55%
5 years
-28.90%
10 years
-6.07%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

272% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $996K

44% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 27

5% more funds holding

Funds holding: 184 [Q3] → 194 (+10) [Q4]

1.23% more ownership

Funds ownership: 93.08% [Q3] → 94.31% (+1.23%) [Q4]

3% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 64

4% less capital invested

Capital invested by funds: $737M [Q3] → $704M (-$32.8M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$37
84%
upside
Avg. target
$39
94%
upside
High target
$41
104%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Baird
Catherine Ramsey
50% 1-year accuracy
8 / 16 met price target
84%upside
$37
Outperform
Maintained
28 Feb 2025
Stephens & Co.
Mason Carrico
32% 1-year accuracy
9 / 28 met price target
104%upside
$41
Overweight
Reiterated
2 Jan 2025

Financial journalist opinion

Based on 5 articles about CSTL published over the past 30 days

Neutral
Business Wire
2 weeks ago
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.
New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
Neutral
Seeking Alpha
3 weeks ago
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Tom Peterson - Baird Vidyun Bais - BTIG Kyle Mikson - Canaccord Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
3 weeks ago
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago.
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
Neutral
Business Wire
4 weeks ago
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
Neutral
Business Wire
4 weeks ago
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.
Castle Biosciences to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
1 month ago
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Positive
Zacks Investment Research
1 month ago
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
Neutral
Business Wire
1 month ago
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, Feb. 14-19.
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
Positive
Zacks Investment Research
1 month ago
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Charts implemented using Lightweight Charts™